Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at $490,590. The trade was a 12.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, March 24th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $22,500.00.
• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.

Enliven Therapeutics Stock Down 6.6 %

NASDAQ:ELVN traded down $1.39 on Monday, reaching $19.68. The stock had a trading volume of 574,086 shares, compared to its average volume of 276,157. The company has a market capitalization of $964.40 million, a P/E ratio of -10.36 and a beta of 1.04. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03. The stock has a fifty day moving average price of $21.28 and a 200-day moving average price of $23.74.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ELVN shares. HC Wainwright upped their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st. BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $38.75.

Institutional Trading of Enliven Therapeutics

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics in the fourth quarter worth about $97,000. BNP Paribas Financial Markets bought a new position in shares of Enliven Therapeutics in the fourth quarter worth about $112,000. ExodusPoint Capital Management LP acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $200,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $228,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.